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Percutaneous coronary intervention for refractory spasm: a monocen-
tric restropectiv study
Marie Caroline Chenilleau [Orateur] (1), Stéphane Manzo Silberman (1), 
Aures Chaib (1), Hélène Aelion (1), Michel Lerecouvreux (2), Simon 
Weber (1), Olivier Varenne (1)
(1) Cochin, Paris, France – (2) hopital percy, Clamart, France
Between 5 and 30% of variant angina are refractory to a maximal vaso-
dilator medication; however the prognosis could be strong. In case of focal 
spasm, stenting could be an alternative therapeutic. We decided to analyse this 
population who required a percutaneous coronary intervention (PCI), to deter-
mine whether it would be possible to identify factors in their clinical, angio-
graphic characteristics.
Retrospectively, we included 173 patients between 2004 and 2010 in the 
hospital Cochin, who where diagnosed for a variant angina by a spasm pro-
vocative test: positive test was de¿ ned by the reduction of >50% of lumen 
arteries’. In a second time, we compared the patients who are well controled 
by vasodilator drug (n=81) with the population who required a PCI because 
of a focal refractory spasm (n=18): persistence of a vasoreactivity during the 
challenge test under maximal medication. The population included majority 
men (62%), with a medium age of 55.6 +/- 11.7 years old. In our practice, 
most, 90% of the coronary angiography and challenge test were performed 
by radial access.The patients with focal refractory spasm had most fre-
quently a non signi¿ cant atheroma lesion. In this group, the patients were 
admitted in a more critical presentation: 12.5% cardiac arrest (vs 2.7%), 
12.5% STEMI (vs 0%). The three coronary arteries were equally affected 
by spasm with a mean diameter of 3.8+/-0.65mm. The median time between 
the ¿ rst challenge test and the PCI was around seven days. Drug eluding 
stents (DES) as bare metal stents (BMS) were equally implanted. None 
of the patient died during the follow-up (median 14.7 months, maximal 
4 years). After PCI, 2 patients kept symptoms because of a intrastent reste-
nosis, and 2 with a new positive challenge test (one on an other artery, one 
with medical treatment interruption).
To our knowledge, we report the most important serie of focal variant 
angina treated by PCI. There was no factor identi¿ ed as predictive of the 
medication ef¿ ciency; a systematic control of reversibility of the challenge 
test under medical therapy have to be done. PCI for focal refractory spasm 
could be effective and safe.
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Accuracy of the Door-to-Balloon time for assessing the result of inter-
ventional reperfusion strategy in acute ST-segment elevation myocar-
dial infarction
Jean-Louis Georges [Orateur] (1), Imen Fatnassi-Belhaj (1), Géraldine 
Gibault-Genty (2), Jean-Paul Aziza (2), Elodie Blicq (1), Nicolas Baron (1), 
Bernard Livarek (2)
(1) Centre Hospitalier de Versailles, Cardiologie, Le Chesnay, France – 
(2) Hopital André Mignot, CHV, Cardiologie, Le Chesnay, France
Clinical guidelines recommend that primary percutaneous coronary inter-
vention (PCI) should be performed within 90 minutes of hospital admission 
in patients with acute ST-segment elevation myocardial infarction (STEMI). 
The Door-to–Balloon time (D2B) is widely used to measure the performance 
of interventional centres.
The aim of this study is to evaluate the clinical accuracy of D2B in primary 
PCI.
From January 2007 to March 2008, 173 patients were admitted within 
24 hours of a STEMI in our institution, and 87 were referred <12 hours for a 
direct coronary angiography (47 by mobile medical emergency unit, 40 by the 
emergency department of the institution).
The median time from the onset of pain to the ¿ rst medical contact 
was 96 minutes (interquartile range [IQR] 41-220 minutes), and the time 
 TOPIC 01-4 – Coronary angioplasty
May 12th, Thursday 2011
0076
Impact of the type of stent on 1 year outcomes after PCI in ‘real life’
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J. Silvain (1), F. Beygui (1), R. Choussat (1), E. Berman (1), Jean Philippe 
Collet (1), G. Montalescot (1), Jean Philippe Metzger (2), C. Le Feuvre 
[Orateur] (1)
(1) CHU Pitié Salpêtrière, Département de Cardiologie Médicale, Paris 
Cedex 13, France – (2) CHU Pitié-Salpêtrière, Département de cardiologie, 
Paris, France
Aim: To compare clinical outcomes in consecutive patients treated by per-
cutaneous coronary intervention (PCI) according to the type of stent used: 
1) BMS vs. DES, 2) Sirolimus- (SES) vs. Paclitaxel- (PES) vs. Zotarolimus- 
(ZES) vs. Everolimus eluting stent (EES).
METHODS Among 2334 PCI performed over two years, consecutive 
patients treated successfully with only one kind of stent were included. Patients 
with MI, cardiogenic shock or out-of-hospital cardiac arrest were excluded.
We compare the occurrence of 1) TVF (CV death, Target vessel MI, TVR), 
2) Target Lesion Revascularization (TLR) and 3) de¿ nite Stent Thrombosis 
(ST) at one year.
Results:  Twelve hundred sixty patients ful¿ lled inclusion criteria, 615 
(49%) had BMS, 645 (51%) DES. Among the DES group, 187 (29%) had 
SES, 171 (27%) PES, 206 (32%) ZES, 67 (10%) EES and 14 (2%) others.
Patients in the BMS group were older, had more comorbidities, the mean 
stent length was lower and the average stent diameter higher, compared to 
DES.
Clinical and procedural characteristics were well matched between the dif-
ferent type of DES, except for a lower mean and total stent length in the PES 
group,
TVF according to the type of stent are shown in the ¿ gure. TLR was higher 
after BMS implantation (9.9% vs. 4.3%, p=0.002) without any difference 
between the different type of DES. The de¿ nite stent thrombosis rates were 
comparable whatever the stent used.
Independent predictors of TVF were BMS (OR 2.089; 95%CI 1.345-3.115, 
p<0.001), EES (OR 0.127; 95%CI 0.017-0.956, p=0.045) as hypertension, 
prior PCI and renal failure.
Conclusions: In ‘real life’, BMS appears to be independently correlated 
with an excess of TVF, partly explained by the higher risk feature of the popu-
lation. All kind of DES are similarly associated with a lower TLR rate without 
any excess of stent thrombosis at one year. EES appears independently asso-
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Prevailing effects of tissue cortisol compared to aldosterone in human 
atherosclerotic remodeling
Liliana Legedz [Orateur], Hanene Ayari, Pierre Lantelme, Jacques Randon, 
Patrick Feugier, Giampiero Bricca
Université LYON 1, Lyon, France
Our objective was to characterize the expression of corticoid system com-
ponents and their main target genes in arterial wall as well as the regula-
tion of this expression in VSMC with contractile or adipocyte-dedifferentiated 
phenotype.
The carotid endarterectomy samples of 42 patients were dissected in the 
atheroma plaque and the macroscopically intact tissue (MIT). Real time 
RT-PCR, western blotting and radioimmunoassay were used to assess the 
expression of genes of interest. The cortisol and À udrocortisone treatments of 
VSMC were carried out.
The GRD and 11EHSD1 expression was several times higher than MR and 
11EHSD2 ones within the carotid wall, and this difference was more marked 
in the atheroma compared to MIT, resulting from a decrease in MR expres-
sion and an increase in 11EHSD1 one in the atheroma. Cortisol increased 
the GRD and 11EHSD1 mRNA levels in VSMC and diminished the MR 
one. Fludrocortisone only decreased the MR mRNA level. The MCP-1 and 
collagen I were up-regulated only by glucocorticoids. In presence of car-
benoxolone, the responses of MCP-1 and collagen I to cortisol remained only 
GRD-dependant. After adipocyte dedifferentiation of VSMC the 11E-HSD1 
was increased while the MR and 11E-HSD2 were markedly decreased. The 
collagen I mRNA was this time up-regulated in response to both cortisol and 
also À udrocortisone.
The glucocorticoid pathway expression and activity is higher than mine-
ralocorticoid ones particularly in the atheroma plaque or in adipocyte-dedif-
ferentiated VSMCs, likely due to the cortisol property to up-regulate its 
own production and action with simultaneous down-regulation of aldoste-
rone ones. The prevailing glucocorticoid involvement is con¿ rmed by cor-
tisol-dependent up-regulation of the collagen I and MCP-1 mRNAs whereas 
À udrocortisone stimulates the collagen I expression only after adipocyte 
dedifferentiation of VSMCs. There is no «illicit» cortisol-dependent activa-
tion of MR-receptor. 
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CB1 cannabinoid receptor antagonism inhibits balloon-induced ne-
ointima formation in atherosclerosis-prone mice
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Graziano Pelli (4), Sébastien Lenglet (4), Andreas Zimmer (5), Pal 
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Balloon-induced arterial injury stimulates vascular smooth muscle cell pro-
liferation and inÀ ammatory cell recruitment, which may result in restenosis of 
the diseased vessel. Increasing evidence suggests an increase of endocannabi-
noid levels in different pathological processes, leading to enhanced activation 
of their corresponding cannabinoid receptors, CB1 and CB2. The protective 
effects of CB1 receptor antagonism in atherosclerotic mice and in vitro inhi-
bition of vascular smooth muscle cell proliferation and migration point to a 
potential interest of CB1 receptor blockade in restenosis. The objective of this 
study was to investigate the therapeutic bene¿ t of the selective CB1 receptor 
antagonist AM281 in balloon-induced neointima formation.
from ¿ rst medical contact to admission in the cathlab (Door) was 81 minutes 
(IQR  55-123 minutes). Median times of interventional coronary procedures 
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D2B was unavailable in 22 patients (25%), because of a sponta-
neous TIMI 3 À ow reperfusion without indication for immediate PCI in 
18 (20.8%), contra-indication for PCI in 3 (3.4%)(distal occlusion, culprit 
vessel  diameter <2 mm), and failure in the guide wire crossing of the occlu-
sion in 1 patient (1.1%). In contrast, Door-to-Reperfusion time, assessed by 
a TIMI 3 À ow without no-reÀ ow, was available in 83 patients (95%), and 
shorter than D2B.
Conclusion: Although it is a feasible and reproducible process performance 
measure, D2B time is weakly associated with the outcome of the interven-
tional reperfusion strategy in acute STEMI. This performance measure should 
be associated with an outcome performance measure, such as the rate of TIMI 
3 À ow achieved by primary PCI, or the Door-to-TIMI 3 À ow reperfusion time.
0289
Implication of the Notch pathway in the regulation of the Adenlyl Cy-
clase (AC) 8 expression marking vascular smooth muscle cell (VSMC) 
trans-differentiation
Zela Keuylian [Orateur], Jeroen De Baaij, Véronique Mateo, Isabelle 
Limon, Martine Glorian
Pierre and Marie Curie University, UR4 Viellissement, Stress, InÀ ammation, 
Paris, France
VSMC transdifferentiation, or their switch from a contractile/quiescent to 
a secretory/inÀ ammatory/migratory state, is known to play an important role 
in pathological vascular remodelling including atherosclerosis and post-angio-
plasty restenosis. Several reports have established the Notch pathway as tightly 
regulating VSMC response to several stress factors through growth, migra-
tion, apoptosis and de-differentiation. More recently, we showed that altera-
tions of Notch pathway also govern VSMC acquisition of the inÀ ammatory 
state (Clement, 2007), one of the major events accelerating atherosclerosis. In 
2006, we evidenced that the inÀ ammatory context of atherosclerosis triggers a 
de novo expression of AC isoform 8, and showed, over the past several years, 
that there is a cause to effect relationship between this phenomenon and the 
properties developed by transdifferentiated VSMCs (Clement, 2006; Gueguen, 
2010). The importance of AC8 de novo expression in atherogenesis has been 
further highlighted by our preliminary data obtained in [AC8 x ApoE] double 
KO mice compared to [ApoE] KO mice indicating that AC8 de¿ ciency com-
promises atherosclerosis development in pro-atherogenic [ApoE] animals. As 
an initial approach to understanding the regulation of AC8 expression, we exa-
mined the role of the Notch pathway. We show that the inhibition of Notch 
pathway (using a potent inhibitor of J-secretase-complex, or a siRNA silen-
cing Notch receptors or their target genes) enhances IL-1E’s effect on AC8 
expression; conversely, Notch activation achieved by coculturing IL1E-treated 
VSMCs with murine cells expressing Notch ligand Jagged1 resulted in bloc-
king AC8 transcript expression. In the balloon-injury rat carotid model of 
restenosis AC8’s de novo expression coincided with the down-regulation of 
Notch3 pathway. The impact of reintroducing Notch3 (adenovirus strategy) 
on AC8 expression and neointimal formation occurring in this model is cur-
rently being explored. 
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Background: Premature discontinuation of antiplatelet therapy or reduced 
adherence has been identi¿ ed as major risk factors for stent thrombosis and 
poor prognosis after acute coronary syndrome.
Purpose: This study aimed at identifying correlates of non adherence to 
aspirin among patients undergoing coronary stenting.
Methods: We prospectively included all patients undergoing coronary sten-
ting in our institution. Response to aspirin was assessed during hospital phase 
with arachidonic acid-induced platelet aggregation (AA-Ag) and good res-
ponders to aspirin (AA-Ag<30%) were included in the study for longitudinal 
assessment. (N=308). Response to aspirin was reassessed one month after 
hospital discharge and non responders received a directly observed intake 
of aspirin to exclude de¿ nite biological non response due to bioavailability 
problems. After excluding patients with bioavailability problems, response 
to aspirin based on platelet function testing was used to estimate non adhe-
rence to aspirin after coronary stenting. A logistic regression model was used 
to identify predictors of non adherence.
Results: Non adherence to aspirin concerned 14% of the study sample 
(n=43). After adjustment for age, migrants reported the highest risk of non 
adherence to aspirin (OR[95% CI]: 8.3[3.5-19.8] followed by patients recei-
ving treatment for diabetes (4.5[1.9_10.9]. Individual reporting smoking 
habits had a threefold risk of non adherence (3.1[1.4-6.9]).
Conclusions: Non adherence to aspirin is relatively frequent in a popula-
tion at high risk of cardiovascular events. Appropriate case management and 
special interventions targeting these at higher risk groups need to be imple-
mented to avoid fatal events and assure long term response to treatment.
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Five-Year Clinical Outcome in Patients with Small Vessel Disease 
Treated with Drug-Eluting Versus Bare-Metal Stenting
Etienne Puymirat [Orateur] (1), Fabio Mangiacapra (2), Aaron Peace (2), 
Micaela Conte (2), Jozef Bartunek (2), Marc Vanderheyden (2), William 
Wijns (2), Bernard De Bruyne (2), Emanuele Barbato (2)
(1) Hôpital Européen Georges Pomipdou (HEGP), Cardiologie, Paris, 
France – (2) Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgique
Objective: To assess the clinical impact of drug-eluting stents (DES) vs. 
bare-metal stents (BMS) in the treatment of small coronary vessel lesions.
Background: Stenting is known to be more effective than balloon angio-
plasty in patients with small vessel coronary disease. However it is remains 
unclear if DES are more ef¿ cacious than BMS in this setting.
Methods: From January 2004 to December 2008, all patients were treated 
with percutaneous coronary intervention and stenting in native small coronary 
vessels (de¿ ned as a reference vessel diameter<3mm) were enrolled irrespec-
tive of indication. Patients were divided into two groups according to type of 
stent used: BMS group and DES group. Procedural and long-term clinical out-
comes were compared between the both groups.
Results: A total of 645 patients were enrolled (368 treated with BMS, 
277 with DES). Clinical follow up was obtained in 99.3% (median follow-
up: 3.3±1.2 years; range to 12-60 months). At ¿ ve years, patients treated 
with DES showed signi¿ cantly higher ¿ ve-year major adverse cardiac events 
(MACE)-free survival (HR 0.45, 95%CI 0.29-0.72, log-rank P=0,001) and 
target vessel revascularization (TVR)-free survival (HR 0.44, 95%CI 0.25-
0.78, log-rank P=0,005). There were no signi¿ cant differences between the 
two groups regarding death, acute myocardial infarction and peri procedure-
myocardial infarction. The incidence of stent thrombosis was also similar 
in both groups.
Conclusions:  DES is more effective than BMS in reducing MACE and 
TVR in small vessel disease. However, the use of BMS does not increase mor-
tality or re infarction and so is reasonable to consider in selected cases.
We performed left common carotid balloon distension injury in weight-
matched (25-30g) male apolipoprotein E-de¿ cient (ApoE-/-) mice fed on 
high cholesterol (1.25%) diet for 8 weeks before the intervention. Littermates 
were randomly assigned to receive daily intraperitoneal injection of either the 
synthetic CB1 antagonist AM281 (10 mg/kg) or vehicle control (n=6 per group), 
with the ¿ rst injection given 30 minutes before balloon injury. After 7 days, 
we found signi¿ cantly reduced numbers of medial nuclei (vehicle: 141.1±14.57; 
AM281: 86.44±19.35; p=0.0239) and intimal nuclei compared to vehicle treat-
ment (vehicle: 44.94±5.933; AM281: 29.94±5.815; p=0.0506) in injured vessels 
of AM281-treated mice, indicating reduced medial smooth muscle cells proli-
feration. Immunohistochemical analysis revealed signi¿ cantly reduced staining 
for CD68-positive macrophages (vehicle: 3836±1887; AM281: 987.3±486.1; 
p=0.0206) within dilated arteries of AM281-treated mice.
Our data indicate a critical role of CB1 receptors in neointima formation in 
response to acute arterial injury. The putative effects of CB1 receptor inhibi-
tion on endothelium regeneration after injury remain to be investigated.
0463
In vivo detection of non-occlusive thrombi in drug-eluting stents by 
scintigraphy and radio-labelled Annexin V in a rabbit model
Mohammed Nejjari [Orateur] (1), Graciella Pavon-Djavid (2), Anne 
Meddahi-Pellé (2), Francis Blackwell (1), Laurent Feldman (1), Fabien 
Hya¿ l (1)
(1) HOPITAL BICHAT, Paris, France – (2) inserm U698, Paris, France
Introduction: Non occlusive thrombi are often in contact with non re-
endothelialized stent struts of drug-eluting stent (DES) and could favor stent 
thrombosis. Annexin V radio-labelled with 99mTechnetium (99mTc) is a radio-
tracer with a high af¿ nity for activated platelets.
Objectives: Our objectives were to develop an animal model of non-occlu-
sive thrombosis of stents and to evaluate the ability of annexin V 99mTc for the 
detection of in-stent thrombi using scintigraphy.
Methods: Right carotid arteries of NZW rabbits (n=14) fed a high choles-
terol diet were implanted with DES. Nuclear imaging was performed 10 (n=7) 
or 28 days (n=7) after stent implantation. Rabbits underwent a ¿ rst scinti-
graphy 2 hours after injection of radio-labelled annexin V 99mTc. At the end 
of the ¿ rst scintigraphy, a suture was placed surgically proximal to the injured 
carotid arteries in order to induce a thrombus-prone À ow limiting stenosis. 
Four days later, a second scintigraphy was performed. After the second scin-
tigraphy, stents were excised, imaged ex vivo and then ¿ xed for histological 
examination and scanning electron microscopy (SEM).
Results: Activities measured in vivo in the stented carotid arteries after 
injection of annexin V 99mTc increased on the second scintigraphy after crea-
tion of a surgical stenosis as compared to the ¿ rst scintigraphy (1,2 vs. 1 res-
pectively; p<0.05). On the second scintigraphy, activities were higher at 14 
vs. 32 days after stent implantation (22 vs. 11 counts/pixel/ MBq, respecti-
vely; p<0.05). DES were re-endothelialized only 32 days but not 14 days after 
implantation on histological sections and SEM. High activities measured ex 
vivo in stents by scintigraphy were associated with the detection of thrombi on 
corresponding histological sections.
Conclusions: In this study, we developed a rabbit model of non-occlusive 
thrombosis of non re-endothelialized DES in carotid arteries. In this model, in-
stent thrombi could be detected using annexin V 99mTc scintigraphy.
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Non adherence to aspirin in patients undergoing coronary stenting: as-
sociated factors and implications for intervention and clinical manage-
ment
Thomas Cuisset [Orateur] (1), Jacques Quilici (1), Mathieu Pankert (1), 
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